LexDanaLexDanabeta
Inventor

Scott R. Presnell

Inventor
Tacoma, WA, US

Overview

126→
Patents
2000–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 126 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
A61KPreparations for medical, dental or toiletry purposes20%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
C12NMicroorganisms or enzymes6%
A01KAnimal husbandry5%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests5%
C07HSugars2%
Y10TTechnical subjects covered by former us classification1%
A61BDiagnosis0%
PatentTitleYear
11,013,814Cartilage-homing peptide conjugates and methods of use thereof202110,640,575Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases202010,562,967Treating inflammation with IL-17/IL-23 bispecific antibodies202010,358,490Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies201910,358,489IL-23p19 monoclonal antibodies201910,023,656Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies201810,000,563Monoclonal antibodies that bind both IL-17A and IL-17F20189,994,634Use of an IL-17/IL-23 bispecific antibody for treating inflammation20189,783,606'Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies'20179,708,401'IL-17A/F cross-reactive monoclonal antibodies and methods of using the same'20179,708,390'Compositions and methods for inhibiting PDGFRbeta and VEGF-A'20179,663,572'Antibodies that bind both IL-17A and IL-17F'20179,464,134'Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19'20169,441,034'Compositions and methods for inhibiting PDGFRβ and VEGF-A'20169,416,183'Methods of treating inflammatory diseases using antibodies that bind both IL-17A and IL-17F'20168,992,922'Antagonists of IL-17A, IL-17F, and IL-23P19'20158,945,553'Bispecific antibodies to IL-23 and IL-17A/F'20158,871,467'Polynucleotides encoding antibodies that bind both IL-17A and IL-17F'20148,648,182'Polynucleotides encoding antibodies to cytokine receptor zcytor17'20148,609,099'Antibodies that bind both IL-17A and IL-17F'20138,557,544'Polynucleotides encoding antibodies that bind both IL-17A and IL-17F'20138,496,936'Antagonists of IL-17A, IL-17F, and IL-23P19'20138,481,288'Polynucleotides encoding antibodies that bind both IL-17A and IL-17F'20138,475,791'Anti-IL-TIF antibodies and methods of use'20138,383,775'Cytokine zalpha11 ligand'20138,372,602'Methods for producing cytokine receptor ZALPHA11'20138,333,968'Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19'20128,309,692'Antibodies to cytokine receptor ZCYTOR17'20128,268,773'Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist'20128,227,575'Cytokine zalpha11 ligand antibodies'20128,227,579'IL-23 antagonists'20128,217,008'Methods of treating inflammatory disease using a soluble IL-20 receptor'20128,124,077'Anti-IL-TIF antibodies and methods of making'20128,110,372'Methods for detecting modulators of cytokine receptor zalpha11'20128,110,180'Method of use of cytokine ZALPHA11 ligand'20128,101,381'Human cytokine receptor'20128,034,784'Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16'20118,017,343'Cytokine zalpha11 ligand antibodies and methods of use'20117,998,468'Cytokine zalpha11 ligand antibodies'20117,947,474'Nucleic acid encoding cytokine receptor ZCYTOR17'20117,923,212'Antibodies to cytokine receptor zalpha11'20117,923,208'Human cytokine receptor'20117,919,595'Antibodies to interferon-like protein Zcyto21(IL29)'20117,910,701'Interleukin-17 receptor homologue'20117,910,703'Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use'20117,851,594'Human cytokine receptor'20107,833,520'Method of using interferon-like protein ZCYTO21(IL-29) to treat hepatitis B'20107,829,075'Method for expanding hematopoietic cells using cytokine zalpha11 ligand'20107,812,130'Human cytokine receptor'20107,790,862'IL-17 and IL-23 antagonists and methods of using the same'20107,790,163'Antibodies that bind both IL-17A and IL-17F and methods of using the same'20107,790,851'Human cytokine receptor'20107,763,713'Zalpha11 cytokine receptors'20107,667,000'Antibodies to Zcytor 16'2010RE041129'Cytokine zalpha11 ligand polynucleotides'20107,655,223'Method of using interferon-like protein ZCYTO21 (IL-29) to treat hepatitis C'20107,642,345'Polynucleotides encoding human cytokine receptor'20107,641,899'Methods for inhibiting IL-TIF-induced proliferation of hematopoietic cells using the cytokine receptor Zcytor16'20107,638,286'Antibodies to cytokine receptor zalpha11'20097,638,602'Human cytokine receptor'20097,629,452'Polynucleotides encoding soluble zalpha11 cytokine receptors'20097,626,002'Cytokine zalpha11 ligand antibodies'20097,619,071'Antibodies that bind interleukin-17 receptor homologue'20097,615,611'Human cytokine receptor'20097,611,699'Methods of using cytokine zalpha11 ligand'20097,612,191'Polynucleotides encoding interleukin-17 receptor homologue'20097,608,452'Polynucleotides encoding cytokine receptor zcytor19'20097,608,426'Polynucleotides encoding mammalian cytokine-like factor 7'20097,601,809'Cytokine receptor zcytor19'20097,592,425'Cytokine zalpha11 ligand fusion proteins'20097,585,948'Soluble interleukin-20 receptor'20097,579,441'Cytokine zalpha11 ligand fusion proteins'20097,572,892'Cytokine zalpha11 ligand fusion proteins'20097,569,670'Cytokine zalpha11 ligand fusion proteins'20097,563,568'Method for detecting activated CD3+ T-cells'20097,534,575'Method for detecting cancer using an antibody to Zcytor16'20097,521,208'Vectors encoding interleukin-17 receptor homologue'20097,521,537'Cytokine receptor zcytor17'20097,517,958'Interleukin-17 receptor homologue'20097,498,154'Nucleic acid encoding a human interferon-like protein Zcyto21'20097,495,080'Cytokine receptor zcytor17'20097,494,804'Polynucleotide encoding cytokine receptor zcytor17 multimer'20097,491,800'Cytokine zalpha11 ligand fusion proteins'20097,491,809'Polynucleotides encoding human cytokine receptor'20097,485,700'Interferon-like protein ZCYTO21'20097,473,765'Cytokine zalpha11 ligand'20097,445,913'Nucleic acid encoding a human allelic variant of interferon-like protein ZCYTO21'20087,427,494'Nucleic acid encoding cytokine receptor zcytor17'20087,411,056'Polynucleotides encoding cytokine receptor zalpha11'20087,410,780'IL-21 antagonists'20087,387,780'Soluble interleukin-20 receptor'20087,351,555'Mouse cytokine receptor Zcytor16'20087,265,203'Human cytokine receptor'20077,252,969'Interferon-like protein Zcyto21'20077,253,261'Interferon-like protein Zcyto21'20077,241,870'Interferon-like protein Zcyto21'20077,217,790'UMLR polypeptides'20077,189,839'Isolated polynucleotides encoding a human cytokine receptor human cytokine receptor'20077,186,805'IL-21 antagonists'20077,153,937'Mammalian cytokine-like factor 7'20067,122,342'Protease-activated receptor PAR4 (ZCHEMR2)'20067,122,632'Soluble Interleukin-20 receptor'20067,084,253'Protease-activated receptor PAR4 (ZCHEMR2)'20066,929,932'IL-21 antagonists'20056,927,040'Interferon-like protein Zcyto21'20056,902,729'Murine interferon-α'20056,897,292'Human cytokine receptor'20056,875,845'Mouse cytokine receptor'20056,822,082'Polynucleotides for mammalian secreted protein, Z1055G2P'20046,803,451'Cytokine receptor zalpha11 polypeptides'20046,777,539'Soluble zalpha11 cytokine receptors'20046,703,224'Zcys6: a member of the cystatin superfamily'20046,692,924'Methods of using cytokine receptor zalpha11 to detect its ligands'20046,686,178'Cytokine zalpha11 ligand polynucleotides'20046,630,571'Mammalian growth factor-7'20036,605,272'Methods of using zalpha11 ligand'20036,576,744'Cytokine receptor zalpha11'20036,548,056'Murine interferon-'20036,528,621'Mammalian cytokine-like factor-7'20036,514,741'Tryptase-like polypeptide ztryp1'20036,500,928'Mammalian cytokine-like factor 7'20026,436,400'Protease-activated receptor PAR4 ZCHEMR2'20026,312,924'Murine interferon-.alpha.'20016,307,024'Cytokine zalpha11 Ligand'20016,271,343'Mammalian cytokine-like receptor 5'20016,111,075'Protese-activated receptor PAR4 (ZCHEMR2)'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2020Patents assigned to ZYMOGENETICS INC (114)· patent assignee history
2000–2017Based in Seattle, WA, US· patent location history
2001–2021Based in Tacoma, WA, US· patent location history
2012–2016Patents assigned to PRESNELL SCOTT R (17)· patent assignee history
2012–2013Patents assigned to HAMMOND ANGELA K (5)· patent assignee history
2012–2013Patents assigned to JASPERS STEPHEN R (5)· patent assignee history
2015–2019Patents assigned to BRISTOL MYERS SQUIBB CO (5)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ZYMOGENETICS INC1142000–2020
PRESNELL SCOTT Rself172012–2016
BRISTOL MYERS SQUIBB CO52015–2019
HAMMOND ANGELA K52012–2013
JASPERS STEPHEN R52012–2013
Locations
LocationPatentsSpan
Tacoma, Washington, US1212001–2021
Seattle, Washington, US52000–2017